Geriatric Exclusivity? Incentives For Research In Elderly Debated At National Academies Workshop

 
• By Michael McCaughan

FDA principal deputy commissioner Amy Abernethy and former commissioner Robert Califf point to success of orphan drug and pediatric exclusivity incentives in spurring drug development for neglected populations.

Carrot lure on a string
New incentives could help spur drug R&D in elderly patients. • Source: Shutterstock

More from Clinical Trials

More from R&D